Patent · US Active

Humanized GM-CSF antibodies

US7897743B2 · kind B2 · utility

0Cited by

1References

12Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Christoph Renner · Partenstein, DE
Antony Wilks Burgess · Melbourne, AU
Andrew Scott · Melbourne, AU

Key dates

Filing date	Jan 31, 2008
Grant date	Mar 1, 2011
Priority date	—
Expiry date	Sep 17, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/75
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.